Pathstone Family Office, LLC Biogen Inc. Transaction History

Pathstone Family Office, LLC

$15.6 Billion
Q3 2023

A detailed history of Pathstone Family Office, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Pathstone Family Office, LLC holds 5,576 shares of BIIB stock, worth $1.25 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

5,576

Previous 1,521 266.6%

Holding current value

$1.25 Million

Previous $433,000 230.95%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	BUY	$253.3 - $285.89 $1.03 Million - $1.16 Million	4,055 Added 266.6%	5,576 $1.43 Million
Q2 2023 Jan 12, 2024	SELL	$275.25 - $318.06 $1.12 Million - $1.29 Million	-4,055 Reduced 72.72%	1,521 $433,000
Q2 2023 Aug 14, 2023	BUY	$275.25 - $318.06 $55,875 - $64,566	203 Added 15.4%	1,521 $433,000
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $411,522 - $468,913	-1,604 Reduced 54.89%	1,318 $366,000
Q4 2022 Oct 23, 2023	BUY	$252.44 - $306.72 $299,646 - $364,076	1,187 Added 68.41%	2,922 $809,000

Q4 2022 Feb 13, 2023	SELL	$252.44 - $306.72 $51,497 - $62,570	-204 Reduced 6.53%	2,922 $809,000
Q3 2022 Oct 23, 2023	BUY	$194.69 - $268.46 $4,477 - $6,174	23 Added 1.34%	1,735 $463,000
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $41,858 - $57,718	215 Added 7.39%	3,126 $834,000
Q2 2022 Oct 23, 2023	BUY	$187.54 - $223.02 $35,820 - $42,596	191 Added 12.56%	1,712 $349,000
Q2 2022 Aug 15, 2022	BUY	$187.54 - $223.02 $257,304 - $305,983	1,372 Added 89.15%	2,911 $592,000
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $4,069 - $5,126	21 Added 1.38%	1,539 $325,000
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $140,845 - $181,007	629 Added 70.75%	1,518 $365,000
Q3 2021 Nov 16, 2021	SELL	$282.99 - $369.05 $2,829 - $3,690	-10 Reduced 1.11%	889 $251,000
Q2 2021 Aug 31, 2021	BUY	$259.0 - $414.71 $23,569 - $37,738	91 Added 11.26%	899 $311,000
Q1 2021 May 14, 2021	BUY	$242.95 - $284.63 $60,251 - $70,588	248 Added 44.29%	808 $226,000
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $25,279 - $38,052	107 Added 23.62%	560 $137,000
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $117,172 - $155,175	453 New	453 $122,000
Q1 2020 Jun 11, 2020	BUY	$268.85 - $341.04 $184,968 - $234,635	688 Added 800.0%	774 $244,000
Q1 2020 May 07, 2020	SELL	$268.85 - $341.04 $21,776 - $27,624	-81 Reduced 48.5%	86 $27.2 Million
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $78,944 - $87,019	-360 Reduced 68.31%	167 $39,000
Q1 2019 May 14, 2019	SELL	$216.71 - $338.96 $112,039 - $175,242	-517 Closed	0 $0
Q3 2018 Nov 09, 2018	BUY	$293.51 - $383.83 $14,675 - $19,191	50 Added 10.71%	517 $182,000
Q2 2018 Aug 10, 2018	SELL	$257.52 - $306.91 $12,876 - $15,345	-50 Reduced 9.67%	467 $136,000
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $39,019 - $55,186	150 Added 40.87%	517 $142,000
Q4 2017 Feb 12, 2018	SELL	$307.64 - $344.58 $25,534 - $28,600	-83 Reduced 18.44%	367 $117,000
Q3 2017 Nov 14, 2017	SELL	$281.15 - $329.69 $32,894 - $38,573	-117 Reduced 20.63%	450 $120,000
Q2 2017 Aug 16, 2017	BUY	N/A	567	567 $153,000

Others Institutions Holding BIIB

# of Institutions

1,047

Shares Held

126M

Call Options Held

1.37M

Put Options Held

1.35M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $32.3B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.

Account

Pathstone Family Office, LLC Biogen Inc. Transaction History